Treats hypertension. ANDA 210184, held by Zydus Pharms. Nifedipine.
As of Nov 16, 2026, ANDA 210184 (Nifedipine), held by Zydus Pharms, was first approved by FDA on Jun 29, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nifedipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2018 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters